Creacion Ventures

Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, focused on developing and commercializing cost-effective recombinant virus-based therapies. The company aims to create a scalable platform that produces high-quality, affordable rAAV therapies for a range of genetic disorders, including ophthalmic, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has a diverse product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. By prioritizing affordability and quality, the company seeks to enhance the lives of patients through innovative genetic therapies.

MOMA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on discovering precision medicines by targeting molecular machines that are fundamental to human disease. MOMA Therapeutics utilizes a unique platform that leverages the common features of the ATPase target class, which includes significant conformational changes and energy-driven mechanics. By combining these insights with advancements in structural biology and small-molecule drug discovery, MOMA Therapeutics aims to develop drugs targeting previously challenging enzymes, contributing to the next generation of targeted therapies. The company was formerly known as ATPases NewCo, Inc. before rebranding in March 2020.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

MOMA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on discovering precision medicines by targeting molecular machines that are fundamental to human disease. MOMA Therapeutics utilizes a unique platform that leverages the common features of the ATPase target class, which includes significant conformational changes and energy-driven mechanics. By combining these insights with advancements in structural biology and small-molecule drug discovery, MOMA Therapeutics aims to develop drugs targeting previously challenging enzymes, contributing to the next generation of targeted therapies. The company was formerly known as ATPases NewCo, Inc. before rebranding in March 2020.

Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.